Thank You!

Thanks to all the collaborators, clients, family, and friends who made 2023 such a success.

ChatGPTs seasonal poem:

In pharma and chemical realms we are led,With AOP’s insights, we forge ahead,PBK meets QSP in this season of joy,Happy Holidays to all, our spirits high,From our team to yours, may success amplify!

We end with a short review of the year, featuring all things ‘New’!

New colleagues, new collaborations and consortium updates, new platform technology developments, F2F conferences for the new year, and new software developments…

We have grown!

To continue to keep pace with the development of our platforms, Systems Pharmacology, Systems Toxicology, and Software Development we have further strengthened our capabilities across these platforms.

2024 promises to add some further critical positions and we look forward to bringing these new skills to our clients.

Welcome to all our new starters!

 

 

Consortia Collaboration

esqLABS continues to develop the science and plays a significant role in major collaborations across Europe and we are active members of a number of consortium.

Keep posted for more developments from these and our other programmes, ONTOX and ASPIS.

 

 

Virtual Dog

Earlier this year we were delighted to secure the largest funding award for the Phase 2 of the NC3Rs flagship CRACK-IT programme  – Virtual Second Species Mega Challenge.

£1.6M awarded for Phase 2 of the 2021 Virtual Second Species Mega Challenge | Innovation Platform (nc3rs.org.uk)

Cathy Vickers, Head of Innovation at the NC3Rs:

“We’re delighted that the Virtual Second Species Challenge team is now poised to start delivery of the Virtual Dog. The Challenge has the potential to deliver a step-change in the field of toxicological modelling and we are looking forward to working with the esqLABs team, the Sponsors and Partners on this exciting collaboration”.

EFSA ExpoAdvance

esqLABS scientist Lara Lamon works with the ExpoAdvance project – EFSA’s roadmap on aggregate exposure to chemicals in the EU. At the recent 2nd ExpoAdvance workshop, we collected expert opinions on key insights from previous engagement activities and scientific reviews, initiating a crucial feedback process. This valuable input will inform the final prioritization of the identified working areas scheduled for 2024. 

OUR PLATFORM TECHNOLOGIES

We are constantly striving to keep ahead of the science and look at how we can apply the principles of modelling to simulation to these new platforms and technologies. It’s why we have our expert scientists bringing their insights to these technologies. Our platform leads Christian MaassNicoleta Spinu and Pavel Balazki share their reflections:

Digital Twins

If there is one technology that has shone out this year, then Organ-on-Chip and their digital twins must be a candidate! We have been out talking at MPS World Summit-Berlin, GMP-Paris and ISSX-London about these physiologically-relevant systems and how they can combine with digital twins.  In 2024, you can expect more in depth analysis and mechanistic modelling of in vitro data as we look to incorporate other MPS systems such as organoids and 3D spheroids. Or you can catch Dr. Christian Maass at Euroocs-Milan, MPS World Summit-Seattle and EuroTox to discuss opportunities for collaboration! 

Organ-on-Chips and Digital Twins: The key to revolutionizing the drug development process – esqLABS

Software Development

We continues to support the ongoing development of the OSP-Suite, and this year we saw the OSP Software development team release two updates of the OSP Suite. V11.1 and 11.2 saw the implementation of new features like new diagnostic plots, better management of observed data in simulation results plots, and calculation of PK parameters for population simulations. Development of which was sponsored by Boehringer Ingelheim. We also saw the release of esqlabsR, an R package for quality controlled M&S workflows with OSP models and a new R package for Parameter Identification with OSP models. We look forward to the release of Version 12 – release is planned for 1H24 – more to follow! 

Training Platform

esqLABS loves teaching, and 2023 has been no exception as we continue to develop our courses esqLABS Shop. In the last quarter of 2023 alone we have provided public workshops at ACoP, and at the PMX Benelux Meeting in Leiden. We have offered bespoke training courses throughout the year, and next year we shall be running a series of webinars with our in-house experts on topics such as qAOP, OoC, large molecules, radiotherapy. We shall also be looking to provide further insights on our R-Package esqlabsR, so if you developed your R workflow within OSP Suite, we are looking for your ideas for a public webinar to benefit everyone! You will find us on the road too, offering courses at several key conferences throughout the years, such as ESTIV2024 in June. We welcome suggestions and requests for new course development as well as on-demand training at training@esqlabs.com

Open Systems Pharmacology

esqLABS continues to play a prominent role with the Open Systems Pharmacology suite. That’s why our CEO Stephan Schaller was re-elected to chair the management team!

We recognise the importance of open-source for the ease and transparency of the modelling we do at esqLABS – and there is immense societal value in developing this for academic, industry and regulatory use cases.

CONFERENCES AND EVENTS 2024

We hope to catch you next year at the events we shall be attending. Here’s a couple of those events we shall be at, see you there!! 

  • ASCPT – Colorado Springs – March 
  • SOT – Salt Lake City – March  
  • SETAC – Seville – May  
  • ESTIV – Prague – June  
  • PAGE – location to follow – June 
  • EuroTox – Copenhagen – September 
  • ACoP – location to follow – November 

Get in touch now

Contact

esqLABS GmbH | Hambierich 34 | 26683 Saterland | Germany
Tel. +49 151 / 58559070 | info@esqLABS.com

This site does not use cookies to track your personal information